Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead Dr. Shannon Westin (MD Anderson Cancer Center, Houston, TX) and Dr....
December 01, 2022 08:00 ET | Source: Nuvectis Pharma, Inc.

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...
November 08, 2022 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansion portion is expected to begin in Q1 2023 Investigational New Drug...
October 18, 2022 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

FORT LEE, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...
October 03, 2022 16:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the...
September 28, 2022 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment...
September 13, 2022 08:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma

FORT LEE, N.J., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
September 07, 2022 08:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences

FORT LEE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the...
August 05, 2022 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023NXP800 IND Cleared by the U.S. FDA, U.S. and U.K. Sites Now Participating in...
August 01, 2022 08:30 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement

Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...